$5.73
1.96% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US36322Q1076
Symbol
GLTO
Sector
Industry

Galecto Inc Stock price

$5.73
-1.54 21.18% 1M
-10.02 63.61% 6M
-12.27 68.17% YTD
-8.77 60.48% 1Y
-71.02 92.53% 3Y
-369.27 98.47% 5Y
-369.27 98.47% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.11 1.96%
ISIN
US36322Q1076
Symbol
GLTO
Sector
Industry

Key metrics

Market capitalization $7.55m
Enterprise Value $-12.10m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.48
P/B ratio (TTM) P/B ratio 0.34
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-20.14m
Free Cash Flow (TTM) Free Cash Flow $-25.16m
Cash position $19.68m
EPS (TTM) EPS $-19.33
P/E forward negative
Short interest 0.38%
Show more

Is Galecto Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Galecto Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Galecto Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Galecto Inc:

Buy
100%

Financial data from Galecto Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.46 0.46
40% 40%
-
-0.46 -0.46
40% 40%
-
- Selling and Administrative Expenses 11 11
3% 3%
-
- Research and Development Expense 8.16 8.16
74% 74%
-
-20 -20
55% 55%
-
- Depreciation and Amortization 0.46 0.46
40% 40%
-
EBIT (Operating Income) EBIT -20 -20
54% 54%
-
Net Profit -21 -21
54% 54%
-

In millions USD.

Don't miss a Thing! We will send you all news about Galecto Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Galecto Inc Stock News

Neutral
GlobeNewsWire
25 days ago
-  Completed strategic review to focus on oncology and severe liver diseases -  Announced acquisition of global rights to BRM-1420, a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML from Bridge Medicines -  Appointed Dr. Amy Wechsler to the Board of Directors and Matthew Kronmiller as Executive Vice President of Strategy and Chief Business Officer BOSTON, Nov. 01, 2024 (GL...
Neutral
GlobeNewsWire
about one month ago
BOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced the appointment of Dr. Amy Wechsler to its Board of Directors. Dr. Wechsler brings a unique combination of expertise and a proven track record of leadership in the healthcare industry.
Neutral
GlobeNewsWire
about 2 months ago
BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that, following an intensive strategic review process, Galecto has determined to focus on cancer and liver disease, leveraging its existing clinical stage asset GB1211, which has shown positive resu...
More Galecto Inc News

Company Profile

Galecto, Inc. operates as a clinical-stage biotechnology company developing therapeutics which are designed to target the biological processes to treat fibrotic and related diseases including cancer. Its product portfolio includes GB0139, GB1211, GB2064, and GB1211. The company was founded by Ulf Nilsson, Hakon Leffler, Tariq Sethi, and Hans T. Schambye in 2011 and is headquartered in Copenhagen, Denmark.

Head office United States
CEO Hans Schambye
Employees 13
Founded 2011
Website www.galecto.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today